125 related articles for article (PubMed ID: 8325051)
1. Cyclosporine as possible prophylaxis for obstructive airways disease after allogeneic bone marrow transplantation.
Payne L; Chan CK; Fyles G; Hyland RH; Bafundi P; Yeung M; Messner H
Chest; 1993 Jul; 104(1):114-8. PubMed ID: 8325051
[TBL] [Abstract][Full Text] [Related]
2. Prognostic factors for long-term survival in leukemic marrow recipients with special emphasis on age and prophylaxis for graft-versus-host disease.
Aschan J; Ringdén O
Clin Transplant; 1994 Jun; 8(3 Pt 1):258-70. PubMed ID: 8061365
[TBL] [Abstract][Full Text] [Related]
3. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
[TBL] [Abstract][Full Text] [Related]
4. [The analysis of leukemic relapse after allogeneic bone marrow transplantation].
Yoshimura M; Yoshida H; Matsunashi T; Hidaka S; Kobayashi M; Yoshida S; Tominaga N; Tejima H; Hiraoka A; Nakamura H
Rinsho Ketsueki; 1991 Nov; 32(11):1433-8. PubMed ID: 1758050
[TBL] [Abstract][Full Text] [Related]
5. Marked increase in veno-occlusive disease of the liver associated with methotrexate use for graft-versus-host disease prophylaxis in patients receiving busulfan/cyclophosphamide.
Essell JH; Thompson JM; Harman GS; Halvorson RD; Snyder MJ; Johnson RA; Rubinsak JR
Blood; 1992 May; 79(10):2784-8. PubMed ID: 1586725
[TBL] [Abstract][Full Text] [Related]
6. Pulmonary function changes in long-term survivors of chronic myelogenous leukemia after allogeneic bone marrow transplantation: a Taiwan experience.
Chiou TJ; Tung SL; Wang WS; Tzeng WF; Yen CC; Fan FS; Liu JH; Chen PM
Cancer Invest; 2002; 20(7-8):880-8. PubMed ID: 12449718
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate, cyclosporine, or both to prevent graft-versus-host disease after HLA-identical sibling bone marrow transplants for early leukemia?
Ringdén O; Horowitz MM; Sondel P; Gale RP; Biggs JC; Champlin RE; Deeg HJ; Dicke K; Masaoka T; Powles RL
Blood; 1993 Feb; 81(4):1094-101. PubMed ID: 8427991
[TBL] [Abstract][Full Text] [Related]
8. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic cell-mediated immunotherapy using donor lymphocytes for prevention of relapse in patients treated with allogeneic bone marrow transplantation for hematological malignancies.
Naparstek E; Nagler A; Or R; Kapelushnik J; Slavin S
Clin Transpl; 1996; ():281-90. PubMed ID: 9286578
[TBL] [Abstract][Full Text] [Related]
10. Selective depletion of CD8+ cells for prevention of graft-versus-host disease after bone marrow transplantation. A randomized controlled trial.
Nimer SD; Giorgi J; Gajewski JL; Ku N; Schiller GJ; Lee K; Territo M; Ho W; Feig S; Selch M
Transplantation; 1994 Jan; 57(1):82-7. PubMed ID: 8291119
[TBL] [Abstract][Full Text] [Related]
11. Long-term follow-up of immunosuppressive treatment for obstructive airways disease after allogeneic bone marrow transplantation.
Sánchez J; Torres A; Serrano J; Román J; Martín C; Pérula L; Martínez F; Gómez P
Bone Marrow Transplant; 1997 Sep; 20(5):403-8. PubMed ID: 9339757
[TBL] [Abstract][Full Text] [Related]
12. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia.
Bacigalupo A; Van Lint MT; Occhini D; Gualandi F; Lamparelli T; Sogno G; Tedone E; Frassoni F; Tong J; Marmont AM
Blood; 1991 Apr; 77(7):1423-8. PubMed ID: 2009366
[TBL] [Abstract][Full Text] [Related]
13. Cyclosporine combined with methylprednisolone or methotrexate in prophylaxis of moderate to severe acute graft-versus-host disease.
Gondo H; Harada M; Taniguchi S; Akashi K; Hayashi S; Teshima T; Takamatsu Y; Eto T; Nagafuji K; Yamasaki K
Bone Marrow Transplant; 1993 Nov; 12(5):437-41. PubMed ID: 8298553
[TBL] [Abstract][Full Text] [Related]
14. Results of allogeneic bone marrow transplantation for acute leukemia have improved in Europe with time--a report of the acute leukemia working party of the European group for blood and marrow transplantation (EBMT).
Frassoni F; Labopin M; Gluckman E; Prentice HG; Vernant JP; Zwaan F; Granena A; Gahrton G; De Witte T; Gratwohl A; Reiffers J; Gorin NC
Bone Marrow Transplant; 1996 Jan; 17(1):13-8. PubMed ID: 8673048
[TBL] [Abstract][Full Text] [Related]
15. Subclinical pulmonary function defects following autologous and allogeneic bone marrow transplantation: relationship to total body irradiation and graft-versus-host disease.
Tait RC; Burnett AK; Robertson AG; McNee S; Riyami BM; Carter R; Stevenson RD
Int J Radiat Oncol Biol Phys; 1991 Jun; 20(6):1219-27. PubMed ID: 2045296
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation.
Ho VT; Weller E; Lee SJ; Alyea EP; Antin JH; Soiffer RJ
Biol Blood Marrow Transplant; 2001; 7(4):223-9. PubMed ID: 11349809
[TBL] [Abstract][Full Text] [Related]
17. Importance of bone marrow cell dose in bone marrow transplantation.
Paulin T
Clin Transplant; 1992 Feb; 6(1):48-54. PubMed ID: 10150090
[TBL] [Abstract][Full Text] [Related]
18. Late pulmonary impairment following allogeneic bone marrow transplantation.
Beinert T; Düll T; Wolf K; Holler E; Vogelmeier C; Behr J; Kolb H
Eur J Med Res; 1996 Apr; 1(7):343-8. PubMed ID: 9364037
[TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of patients undergoing allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission after cyclophosphamide-total body irradiation and cyclosporine.
Mehta J; Powles R; Treleaven J; Horton C; Tait D; Meller S; Pinkerton CR; Middleton G; Eisen T; Singhal S
Bone Marrow Transplant; 1996 Oct; 18(4):741-6. PubMed ID: 8899189
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporine monitoring improves graft-versus-host disease prophylaxis after bone marrow transplantation.
Ghalie R; Fitzsimmons WE; Weinstein A; Manson S; Kaizer H
Ann Pharmacother; 1994 Mar; 28(3):379-83. PubMed ID: 8193430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
